ArticleNature communications2018
BrlR from Pseudomonas aeruginosa is a receptor for both cyclic di-GMP and pyocyanin.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 55 citations in OpenAlex.
- Cyclic di-GMP directly reprograms the multidrug resistance machinery via UspG-mediated sequestration of RamR in Klebsiella.PLoS pathogens · 2026Article
- The Cyclic Di-GMP Receptor HpoR Modulates Mycobacterial Multidrug Susceptibility by Regulating IniBAC-Mediated Envelope Permeability.Microorganisms · 2026Article
- Differential analysis of the lower respiratory tract microbiota between patients with non-tuberculous mycobacterial pulmonary disease and pulmonary tuberculosis.BMC microbiology · 2026Article
- Herbal extracts as antibiotic adjuvants against ESKAPE pathogens: mechanisms and therapeutic potential.Engineering microbiology · 2026Review
- MexR and NalD are pyocyanin-responsive transcriptional repressors of the efflux pump MexAB-OprM in Pseudomonas aeruginosa.Nucleic acids research · 2025Article
- Myricetin Potentiates Antibiotics Against ResistantBiology · 2025Article
- Multidrug-resistant Pseudomonas aeruginosa in immunocompromised cancer patients: epidemiology, antimicrobial resistance, and virulence factors.BMC infectious diseases · 2025Article
- Genetic Dissection of Cyclic di-GMP Signalling in Pseudomonas aeruginosa via Systematic Diguanylate Cyclase Disruption.Microbial biotechnology · 2025Article
- Correlation Analysis Between Multi-Drug Resistance Phenotype and Virulence Factor Expression of ClinicalCurrent issues in molecular biology · 2025Article
- Article
- Oligoribonuclease mediates high adaptability of P. aeruginosa through metabolic conversion.BMC microbiology · 2024Article
- Precise genome engineering in Pseudomonas using phage-encoded homologous recombination and the Cascade-Cas3 system.Nature protocols · 2023Review
- CvkR is a MerR-type transcriptional repressor of class 2 type V-K CRISPR-associated transposase systems.Nature communications · 2023Article
- Elongation factor P modulatesProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Antibiofilm and Antiquorum Sensing Potential ofFoods (Basel, Switzerland) · 2022Article
- The Vibrio cholerae master regulator for the activation of biofilm biogenesis genes, VpsR, senses both cyclic di-GMP and phosphate.Nucleic acids research · 2022Article
- The role of bacterial signaling networks in antibiotics response and resistance regulation.Marine life science & technology · 2022Review
- Bacterial MerR family transcription regulators: activationby distortion.Acta biochimica et biophysica Sinica · 2022Review
- A novel inactivated whole-cell Pseudomonas aeruginosa vaccine that acts through the cGAS-STING pathway.Signal transduction and targeted therapy · 2021Article
- Antibiofilm peptides: overcoming biofilm-related treatment failure.RSC advances · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The virulence factor pyocyanin and the intracellular second messenger cyclic diguanylate monophosphate (c-di-GMP) play key roles in regulating biofilm formation and multi-drug efflux pump expression in Pseudomonas aeruginosa. However, the crosstalk between these two signaling pathways remains unclear. Here we show that BrlR (PA4878), previously identified as a c-di-GMP responsive transcriptional regulator, acts also as a receptor for pyocyanin. Crystal structures of free BrlR and c-di-GMP-bound BrlR reveal that the DNA-binding domain of BrlR contains two separate c-di-GMP binding sites, both of which are involved in promoting brlR expression. In addition, we identify a pyocyanin-binding site on the C-terminal multidrug-binding domain based on the structure of the BrlR-C domain in complex with a pyocyanin analog. Biochemical analysis indicates that pyocyanin enhances BrlR-DNA binding and brlR expression in a concentration-dependent manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.